Saturday 17 October 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS was flat, free cash flow was flat and total debt rose 79.3%, each against the same quarter a year earlier.
0.75
0.00
0.00%
Follow CTOR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
0.00 | 0.00 | 0.00 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(25.87) | (16.19) | (11.89) | — | |
P/B ratio |
1.74 | 1.76 | 1.50 | — | |
Price to Tangible BV |
1.74 | 1.76 | 1.50 | — | |
EV/Sales |
0.00 | 0.00 | 0.00 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(3.80) | (4.28) | (7.43) | — | |
EV/FCF |
(2.29) | (2.60) | (4.15) | — | |
Quick Ratio |
0.29 | 0.06 | 0.25 | 0.08 | |
Current Ratio |
0.73 | 0.50 | 0.83 | 0.56 | |
Net Debt/EBITDA |
(0.53) | (0.35) | (1.71) | (1.99) | |
Debt/Assets |
18.02% | 11.94% | 13.91% | 13.19% | |
Debt/Equity |
0.50 | 0.34 | 0.26 | 0.30 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.30 | 0.14 | 1.33 | 1.10 | |
Capex/Depreciation |
(1.05) | (0.35) | (7.67) | 0.00 | |
Interest Coverage |
(37.62) | (867.08) | (114.68) | (82.23) | |
Research and Development Expense of Revenue |
14.63% | 64.74% | 25.82% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
520.82% | 1,628.53% | 172.80% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
238.37% | 211.52% | 100.30% | 0.00% | |
Graham Net Nets |
(0.41) | (0.58) | (0.16) | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(72.31%) | (75.81%) | (31.00%) | — | |
Free Cash Flow Yield |
(45.83%) | (44.23%) | (26.29%) | — | |
Revenue per Share |
0.01 | 0.02 | 0.05 | 0.00 | |
Operating CF per Share |
(0.03) | (0.04) | (0.08) | (0.07) | |
Capex per Share |
(0.02) | (0.01) | (0.05) | (0.08) | |
Free Cash Flow per Share |
(0.04) | (0.04) | (0.13) | (0.15) | |
Cash per Share |
0.15 | 0.03 | 0.08 | 0.05 | |
Shareholders Equity per Share |
0.37 | 0.35 | 0.67 | 0.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.37 | 0.35 | 0.67 | 0.61 | |
Free Cash Flow |
(4.71) | (4.43) | (11.75) | (11.24) | |
Working Capital |
(16.08) | (29.39) | (7.56) | (21.95) | |
Capital Expenditures |
(2.00) | (0.60) | (4.40) | (5.75) | |
Net Current Asset Value |
(29.00) | (36.01) | (14.41) | (28.53) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
1.34 | 0.36 | 1.12 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Payables |
7.99 | 8.28 | 8.16 | 8.47 | |
Average Inventory |
19.92 | 19.00 | 18.51 | 15.28 | |
Average Assets |
101.90 | 96.07 | 100.23 | 92.66 | |
Average Common Equity |
36.39 | 35.46 | 49.85 | 45.50 |
Columns are period end dates · fundamentals updated 5 Oct 2026